Fate Therapeutics, Inc.
FATE
$2.44
-$0.06-2.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -30.16M | -31.21M | -32.37M | -32.25M | -34.07M |
| Total Depreciation and Amortization | 2.78M | 2.92M | 3.06M | 3.23M | 3.28M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.75M | 3.44M | 4.94M | 4.15M | 6.13M |
| Change in Net Operating Assets | 1.19M | -5.96M | 1.06M | 504.00K | 73.00K |
| Cash from Operations | -23.43M | -30.82M | -23.31M | -24.37M | -24.59M |
| Capital Expenditure | -80.00K | -239.00K | -1.19M | -2.20M | -1.36M |
| Sale of Property, Plant, and Equipment | -- | -- | 237.00K | 3.00K | 122.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 14.64M | 23.83M | 28.59M | 23.47M | 20.83M |
| Cash from Investing | 14.56M | 23.59M | 27.63M | 21.27M | 19.59M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 412.00K | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.32M | -- | 1.69M | 2.48M | 1.33M |
| Cash from Financing | 1.74M | -- | 1.69M | 2.48M | 1.33M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.14M | -7.24M | 6.01M | -627.00K | -3.67M |